The Utility of Prophylactic Zoledronic Acid in Patients Undergoing Lung Transplantation - A Retrospective Analysis
Osteoporosis is prevalent among lung transplant candidates and is exacerbated post-transplant by immunosuppressive therapy (glucocorticoids and calcineurin inhibitors). Osteoporotic fractures are a significant source of morbidity. Low bone mineral density (BMD) is a well-recognised surrogate for fracture risk. Intravenous zoledronic acid (ZA) effectively prevents the former and reduces the latter in post-menopausal osteoporosis. Many groups, ours included, prophylactically treat lung transplant recipients with bisphosphonates to prevent BMD reduction and reduce fracture rates.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: E. Ng, D. Topliss, M. Paraskeva, E. Paul, S. Sztal-Mazer Tags: 1048 Source Type: research
More News: Cardiology | Heart | Heart Transplant | Lung Transplant | Men | Menopause | Orthopaedics | Osteoporosis | Reclast | Transplant Surgery | Transplants | Zometa